ArticleDermatology and therapy2026

Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel.

Stéphane Dalle et al.PubMed ↗Publisher ↗

No numbers read from the abstract.